Antiplatelet and Antithrombotic Effects of YM337, the Fab Fragment of a Humanized Anti-GPIIb/IIIa Monoclonal Antibody in Monkeys

Summary

The antiplatelet and antithrombotic effects of the Fab fragment of the humanized antiplatelet glycoprotein (GP) IIb/IIIa monoclonal antibody C4G1 (YM337) were investigated in monkeys. First, the relationship between the inhibition of platelet aggregation and the prolongation of bleeding time was studied in rhesus monkeys. YM337 dose-dependently inhibited ex vivo platelet aggregation, with complete inhibition at doses higher than 0.25 mg/kg intravenous injection or 1.5 μg/kg/min infusion. At 0.25 mg/kg bolus injection followed by 1.5 μg/kg/min infusion, YM337 immediately and continuously inhibited platelet aggregation during the 6-h infusion period with platelet aggregation rapidly returning to over 50% of baseline within 1 h after the cessation of infusion. Template-bleeding time was significantly prolonged during the period of complete inhibition of platelet aggregation.

Second, the antithrombotic effects of YM337 were investigated in a photochemically-induced thrombosis model in squirrel monkeys. YM337 at a dose of 1 mg/kg intravenous injection followed by 6 μg/kg/min infusion for 60 min prevented occlusive thrombus formation in all 4 monkeys. In contrast, time to occlusive thrombus formation did not change on intravenous bolus injection of aspirin 17 mg/kg (11.3 ± 5.2 min) or sodium ozagrel (9.4 ± 3.0 min) compared with saline (13.3 ± 4.0 min). YM337 but not aspirin or sodium ozagrel significantly inhibited ex vivo ADP-induced platelet aggregation, while all drugs completely inhibited arachidonic acid-induced platelet aggregation. However, while aspirin and sodium ozagrel inhibited the thromboxane B₂ generation accompanying arachidonic acid-induced platelet aggregation, YM337 had no effect on this variable. Platelet counts and bleeding time showed no significant change in any group in this squirrel monkey model.

These results indicate that YM337, with a short half-life, may be a useful therapeutic agent in patients with thrombotic disorders.

• References

• 1 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1988; 9: 117-156
• 2 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein Ilb-IIIa complex. Blood 1988; 71: 831-843
• 3 Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein Ilb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-786
• 4 Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993; 70: 94-98
• 5 Bruggemann M, Winter G, Waldmann H, Neuberger MS. The immuno-genicity of chimeric antibodies. J Exp Med 1989; 170: 2153-2157
• 6 Co MS, Yano S, Hsu RK, Landolfi NF, Vasquez M, Cole M, Tso JT, Bring-man T, Laird W, Hudson D, Kawamura K, Suzuki K, Furuichi K, Queen C, Masuho Y. A humanized antibody specific for platelet integrin gpIIb/IIIa. J Immunol 1994; 152: 2968-2976
• 7 Iizuka K, Akahane K, Momose D, Nakazawa M, Tanouchi T, Kawamura M, Ohyama I, Kajiwara I, Iguchi Y, Okada T, Taniguchi K, Miyamoto T, Hayashi M. Highly selective inhibitors of thromboxane synthetase. (I) Imi-dazol derivatives. J Med Chem 1981; 24: 1139-1148
• 8 Rosenblum WI, El-Sabban F. Platelet aggregation in the cerebral microcirculation, effect of aspirin and other agents. Circ Res 1977; 40: 320-328
• 9 Sato M, Ohshima N. Platelet thrombus induced in vivo by filtered light and fluorescent dye in mesenteric microvessels of the rat. Thromb Res 1984; 35: 319-334
• 10 Yano S, Suzuki K, Katoh M, Sugita Y, Kaku S, Kawamura K, Masuho Y. Epitopes and biological activities of two monoclonal antibodies to platelet integrin aIIBβ3. J Biochem 1994; 116: 778-786
• 11 Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press; New York: 1988: 630-631
• 12 Yamaki K, Ohishi S. Fluorometric high performance liquid chromatographic analysis of prostaglandin (PG) metabolites: Application to the catabolism of PGE2 and PGF2a in rat and rabbit kidney homogenates. J Pharmacobio-Dyn 1989; 12: 74-79
• 13 Cox D, Motoyama Y, Seki J, Aoki T, Dohi M, Yoshida K. Pentamidine: A non-peptide GPIIb/IIIa antagonist - In vitro studies on platelets from humans and other species. Thromb Haemost 1992; 68: 731-736
• 14 Cook NS, Zerwes H-G, Tapparelli C, Powling M, Singh J, Mettemich R, Hagenbach A. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: Activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemost 1993; 70: 531-539
• 15 Rote WE, Nedelman MA, Mu D-X, Manley PJ, Weisman H, Cunningham MR, Lucchesi BR. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke 1994; 25: 1223-1233
• 16 Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein Ilb/IIIa antagonist. Drugs of the Future 1994; 19: 135-159
• 17 Bemardi MM, Califf RM, Kleiman N, Ellis SG, Topol EJ. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein Ilb/IIIa platelet antibody. Am J Cardiol 1993; 72: 1121-1125
• 18 Frink RJ, Rooney Jr PA, Trowbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196-200
• 19 Sato M, Natori T, Ohshima N. Effects of scavengers of active oxygens on the platelet thrombus formation in microvessels induced by photochemical reaction. In: Tsuchiya M. et al (ed) Microcirc Ann Tokyo; Nihon-Igakukan: 1987: 135-136
• 20 Sato M, Ohshima N. A new experimental model for inducing platelet thrombus in the microvasculature: Basic study on its feasibility. Blood and Vessel 1984; 15: 36-44
• 21 Fukuda T, Sato M, Nakamura Y, Ohshima N, Inagaki Y. Inhibitory effect of trapidil on platelet thrombus formation in the microvessels of rat mesentery. Blood and Vessel 1985; 16: 573-580
• 22 Kawasaki T, Kaku S, Takenaka T, Yanagi K, Ohshima N. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a photochemically induced platelet-rich thrombosis model. J Cardiovasc Pharmacol 1994; 23: 884-889
• 23 Hennekens CH. Role of aspirin with thrombotic therapy in acute myocardial infarction. Chest 1990; 97: 51s-55s
• 24 Koller RL. Prevention of recurrent ischemic stroke. Postgrad Med 1991; 90: 81-84
• 25 Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971; 231: 235-237
• 26 Naito J, Komatsu H, Ujiie A, Hamano S, Kubota T, Tsubosima M. Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol 1983; 91: 41-48
• 27 Hanson SR, Pareti FI, Ruggeri ZM, Marzec UM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA. Effects of monoclonal antibodies against the platelet glycoprotein Ilb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81: 149-158
• 28 Kelly A, Marzec U, Harker D, Chao B, Lumsden A, Maraganore J, Harker L. Antithrombotic effects of applaggin, a novel antiplatelet peptide. Circulation 1990; 82: 2625